Drug toxicity testing for liver cancer patients

Share This Post

Poietis worked with pharmaceutical company Servier to develop a 4D bioprinted liver model that can better predict the liver toxicity of drugs. 

Hepatotoxicity testing is one of the key tests conducted during preclinical trials using study drugs. Bruno Brisson, co-founder of Poietis, said, “The role of the liver is to degrade substances that are toxic to the body into non-toxic products, but sometimes excessive toxicity can cause important liver lesions.” Animal models of human hepatocytes and cell culture are usually used To predict toxicity, but because they cannot fully replicate the processes that occur in the liver of a real human, their accuracy is limited.

Using Poietis’ bioprinting technology, you can better perform tests to predict liver toxicity. Using the company’s laser-assisted bioprinting technology, the liver model contains different types of human liver cells and immune cells, which can be distributed in three dimensions with high precision. Brisson further explained, “Most of the in vitro liver models used for drug analysis are generated using two-dimensional monolayer cell tissue, but this new three-dimensional model better simulates the complex liver multicellular tissue structure. Drug toxicity testing is of great significance. The model will be validated by testing a group of compounds that can or cannot induce liver toxicity. Brisson is expected to complete it within 18 months.


Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation
CAR T-Cell therapy

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation

CAR T cell therapy has shown promising efficacy in treating B-cell lymphoma Richter Transformation, a rare and aggressive disease. This advanced therapy involves genetically modifying a patient’s T cells to target and destroy cancerous B cells. Clinical trials indicate significant response rates, with some patients achieving complete remission. Despite challenges like potential severe side effects, CAR T cell therapy represents a groundbreaking approach, offering hope for improved outcomes in this difficult-to-treat condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy